Standard BioTools: Spatial Predictors of Immunotherapy Response in Triple-Negative Breast Cancer

Understanding patient responses to immune checkpoint blockade (ICB) therapy in triple-negative breast cancer (TNBC) remains a significant challenge. Traditional methods offer limited insights, making it difficult to predict which patients will benefit most. But what if we could examine the tumor microenvironment with unprecedented detail? In this talk, Dr. Giampaolo Bianchini, MD, from the San Raffaele Hospital delves into the power of Imaging Mass Cytometry™ (IMC™) for precision immuno-oncology.